share_log

IX Biopharma: General Announcement-Press Release - Breakthrough Sublingual Wafers Raise NAD+ Levels, Enhance Well-Being in Human Trial

SGX ·  Jul 9 18:57
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.